VeriStrat And Epidermal Growth Factor Receptor Mutation Status Study Results Presented At 16th World Conference On Lung Cancer

DENVER--(BUSINESS WIRE)--WCLC — Biodesix, Inc. today announced new data regarding VeriStrat®, a serum proteomic test, and epidermal growth factor receptor mutation status in a Phase 1B/2 study of cabozantinib +/- erlotinib in advanced non-small cell lung cancer is being presented at the World Conference on Lung Cancer.

Help employers find you! Check out all the jobs and post your resume.